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Abstract
Background: Fibroblastic foci profusion on histopathology and severity of traction bronchiectasis on highresolution
computed tomography (HRCT) have been shown to be predictors of mortality in patients with idiopathic
pulmonary fibrosis (IPF). The aim of this study was to investigate the relationship between fibroblastic foci (FF)
profusion and HRCT patterns in patients with a histopathologic diagnosis of usual interstitial pneumonia (UIP),
fibrotic non-specific interstitial pneumonia (NSIP) and chronic hypersensitivity pneumonitis (CHP).
Methods: The HRCT scans of 162 patients with a histopathologic diagnosis of UIP or fibrotic NSIP (n = 162) were
scored on extent of groundglass opacification, reticulation, honeycombing, emphysema and severity of traction
bronchiectasis. For each patient, a fibroblastic foci profusion score based on histopathologic appearances was
assigned. Relationships between extent of fibroblastic foci and individual HRCT patterns were investigated using
univariate correlation analysis and multivariate linear regression.
Results: Increasing extent of reticulation (P < 0.0001) and increasing severity of traction bronchiectasis (P < 0.0001)
were independently associated with increasing FF score within the entire cohort. Within individual multidisciplinary
team diagnosis subgroups, the only significant independent association with FF score was severity of traction
bronchiectasis in patients with idiopathic pulmonary fibrosis (IPF)/UIP (n = 66, r2 = 0.19, P < 0.0001) and patients with
chronic hypersensitivity pneumonitis (CHP) (n = 49, r2 = 0.45, P < 0.0001). Furthermore, FF score had the strongest
association with severity of traction bronchiectasis in patients with IPF (r2 = 0.34, P < 0.0001) and CHP (r2 = 0.35,
P < 0.0001). There was no correlation between FF score and severity of traction bronchiectasis in patients with
fibrotic NSIP. Global disease extent had the strongest association with severity of traction bronchiectasis in patients
with fibrotic NSIP (r2 = 0.58, P < 0.0001).
Conclusion: In patients with fibrotic lung disease, profusion of fibroblastic foci is strikingly related to the severity of
traction bronchiectasis, particularly in IPF and CHP. This may explain the growing evidence that traction
bronchiectasis is a predictor of mortality in several fibrotic lung diseases.
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Background
Accurate prognostic evaluation in fibrotic lung disease is
important because it guides management decisions. Over
the past 15 years a relatively large body of literature has
emerged reporting clinical, radiologic and histopatho-
logic features and, more recently, biomarkers which may
influence survival in several different fibrotic lung dis-
eases [1–13]. A number of these studies have highlighted
the importance of the fibroblastic focus as a manifest-
ation of active lung injury and in the particular setting of
idiopathic pulmonary fibrosis (IPF), fibroblastic foci
profusion may predict physiologic decline and mortality
[7, 8, 14]. Although a defining feature of IPF, fibroblastic
foci are also present in fibrotic non-specific interstitial
pneumonia (NSIP) and chronic hypersensitivity pneu-
monitis (CHP), albeit less profuse [15–17]. Most patients
with fibrotic lung disease, however, do not undergo surgi-
cal lung biopsy, limiting the clinical utility of fibroblastic
foci evaluation for prognostication purposes. In contrast,
high resolution computed tomography (HRCT) plays an
integral part in the evaluation of patients with diffuse lung
diseases, and several studies have reported on the prog-
nostic significance of several HRCT patterns including
honeycombing [1, 2, 18–20] and, more recently, traction
bronchiectasis [4–6, 18, 21, 22]. To date no attempts have
been made to determine whether a relationship exists be-
tween fibroblastic foci profusion and HRCT patterns;
therefore, the aim of this study is to determine if fibro-
blastic foci profusion is linked to any individual HRCT
pattern. Patients with histopathologic confirmation of
UIP, fibrotic NSIP and CHP were included in the study
in order to capture a full range of fibroblastic foci
profusion.
Methods
Study population
The study population was selected from a histopatho-
logic database containing patients who had undergone
surgical lung biopsy between 1979 and 2010 at the Royal
Brompton and Harefield NHS Foundation Trust. Inclu-
sion criteria for entry to the study were patients who 1)
had undergone diagnostic surgical lung biopsy and had a
histopathologic diagnosis of UIP, fibrotic NSIP or CHP
and 2) had a multidetector HRCT examination performed
within 3 months of the biopsy. Surgical lung biopsies and
HRCTs were clinically indicated in all cases, and for the
purposes of retrospective examination of these data, the
local research ethics committee waived the need for re-
view by an external NHS Research Ethics Committee. Fur-
thermore, informed patient consent was not required by
the local research ethics committee. Permission to access
patient clinical information for the purposes of this retro-
spective evaluation of clinically indicated data was granted
by the local ethics committee. For each patient, the
diagnosis was determined based upon clinical, radiologic
and histopathologic data according to current American
Thoracic Society (ATS)/European Respiratory Society
(ERS) guidelines [23]. Pulmonary function tests (PFTs)
were recorded for each patient if they had been performed
within 3 months of the biopsy date. The composite
physiologic index (CPI) [18] was calculated in each of
the patients for whom PFTs were available, according to
the formula CPI = 91.0 - (0.65 × DLco) - (0.53 × percent
predicted FVC) + (0.34 × percent predicted FEV1). This
index captures the severity of physiologic impairment
due to interstitial lung disease while excluding the con-
tribution from emphysema [24].
Histopathologic evaluation and fibroblastic foci scores
A semiquantitative evaluation of fibroblastic foci pro-
fusion (FF score) was performed using a scale of 0–6.
All cases were scored by one pathologist (AN), and the
second score was undertaken by an experienced pul-
monary pathologist in relation to previous and current
cohort studies (TC, SY, JvdT) [8]. A consensus diagno-
sis of histologic pattern was made for each case. Semi-
quantitative evaluation of fibroblastic foci profusion
has been shown to correlate well with objective fibro-
blastic foci counts [8]. Absence of fibroblastic foci was
scored as 0, and the most profuse score was 6 after the
method described by Nicholson et al. ([8], see Fig. 1).
In cases with biopsies from two different sites, an aver-
age score was taken. The average of each pathologist’s
FF score was calculated to give an overall FF score for
each patient.
Fig. 1 Biopsy proven fibrotic NSIP. MDT diagnosis: idiopathic fibrotic
NSIP. Total disease extent at this level: 40 %. Ground glass opacification:
30 %, extent of reticulation 10 %, extent of consolidation 10 %. Traction
bronchiectasis score in ground glass opacification: 0. Traction
bronchiectasis score in consolidation: 1. Consensed FF score: 0.5
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HRCT protocol and image evaluation
A detailed description of the HRCT protocol, HRCT pattern
definitions and HRCT scoring method can be found in the
online repository. Two thoracic radiologists of 9 and 10 years’
experience scored HRCTs for each patient on the total
disease extent, the extent of four interstitial patterns (ground
glass opacification, reticulation, honeycombing and con-
solidation) and emphysema, at six levels. A score of the
severity of traction bronchiectasis (0–3) was also assigned.
At the end of scoring, each patient had a total disease ex-
tent score, for total extent scores for each of the four
interstitial patterns, a total emphysema extent score and a
total traction bronchiectasis score (examples are shown
in Figs. 1, 2 and 3).
Statistical analysis
Data are given as means with standard deviations (SD),
medians with interquartile range (IQR) or as number of
patients and percentage where appropriate. Statistical
analyses were performed using STATA software (version
12, StataCorp, College Station, TX, USA). The single
determination standard deviation was used to evaluate
interobserver agreement for continuous variables (total
interstitial disease extent, groundglass opacification, fine
and coarse reticulation, honeycombing, consolidation
and emphysema) [25]. The weighted kappa statistic (κw)
was used to evaluate interobserver agreement for cat-
egorical variables (traction bronchiectasis and FF scores)
and was categorized as follows: poor (0 < κw ≤ 0.20), fair
(0.20 < κw ≤ 0.40), moderate (0.40 < κw ≤ 0.60), good
(0.60 < κw ≤ 0.80) and excellent (0.80 < κw ≤ 1.00) [25].
Univariate correlations between FF scores and HRCT
variables were tested using the Spearman rank correl-
ation analysis. Multivariate linear regression models
were constructed to identify independent determi-
nants of FF score using a backward elimination pro-
cedure, starting with all candidate variables, and at
each step removing variables using a Pvalue cut-off of
0.05 until no variables met this cut-off point criterion
for removal. The assumptions of linear regression
were tested and confirmed by inspection of residual-
versus-predictor plots, and heteroskedasticity was
tested for graphically (by inspection of residuals plot-
ted against fitted values) and non-graphically (using
the Cook-Weisberg test for heteroskedasticity). To in-
vestigate the impact of regression outliers, each multi-
variate equation was re-examined after the exclusion
of observations generating the greatest equation lever-
age (identified by inspecting leverage-versus-residual
squared plots).
Results
Patient population baseline characteristics
The initial population comprised 338 patients with semi-
quantitative scores for FF. Exclusions were due to 1) no
multidetector HRCT data available (n = 133), 2) HRCT
study performed more than 3 months before or after the
data of the surgical lung biopsy (n = 20) and 3) histo-
pathologic diagnosis assigned was not UIP, fibrotic NSIP
or CHP (n = 23). The final study population was made
up of 162 patients. Seventeen patients had a biopsy
taken at two different sites. The MDT diagnoses were as
follows: idiopathic NSIP (n = 25), IPF/UIP (n = 66), con-
nective tissue disease related NSIP (n = 18), connective
tissue disease related UIP (n = 4) and CHP (n = 49).
Complete pulmonary function tests within 3 months of
Fig. 2 Biopsy proven fibrotic NSIP. MDT diagnosis: connective tissue
disease related fibrotic NSIP. Total disease extent at this level: 95 %.
Ground glass opacification: 90 %, extent of reticulation 10 %. Traction
bronchiectasis scores in both patterns: 2. Consensed FF score: 0.5
Fig. 3 Biopsy proven UIP. MDT diagnosis: rheumatoid arthritis related
UIP. Total disease extent at this level: 90 %. Ground glass opacification:
60 %, extent of reticulation 25 %, extent of honeycombing 15 %. Traction
bronchiectasis scores in both patterns: 3. Consensed FF score: 3.5
Walsh et al. BMC Medicine  (2015) 13:241 Page 3 of 8
the biopsy date were available in 117 patients. Of the
162 patients enrolled in the study, 60 were female. Mean
age at the time of surgical lung biopsy was 61.3 years
(SD = 13.4). The median interval between surgical lung
biopsy and HRCT was 45 days (IQR = 21.4). A summary
of the patient demographics including mean HRCT
scores and median histopathologic scores is shown in
Table 1. Interobserver agreement for FF scores and trac-
tion bronchiectasis was good (wκ = 0.69 and wκ = 0.63,
respectively). Interobserver agreement for HRCT pattern
scores measured using the single determination standard
deviation ranged from 1.2 % (total disease extent score)
to 6.9 % (extent of reticulation).
Relationships between fibroblastic foci score and HRCT
patterns in fibrotic lung disease
On univariate analysis, the strongest correlation was
between FF scores and traction bronchiectasis scores.
Weaker, but significant correlations were also demon-
strated between FF score and extent of reticulation,
and FF score and extent of honeycombing (Table 2).
Multivariate regression analysis was performed using
FF score as the dependent variable and total disease
extent on HRCT, the four interstitial HRCT patterns
(extent groundglass opacification, reticulation, honey-
combing, consolidation) and traction bronchiectasis
scores as the independent variables. Only increasing
extent of reticulation and increasing traction bronchiec-
tasis scores were independently correlated with FF score
(traction bronchiectasis: P < 0.0001, 95%CI 0.27–0.53,
reticulation P < 0.0001, 95%CI 0.01–0.04). On re-analysis,
omitting 4 outliers identified by inspecting leverage-
versus-residual squared plots, the same variables were
retained in the equation with the same statistical sig-
nificance (traction bronchiectasis, P < 0.0001, extent of
reticulation, P < 0.0001).
To determine whether this link was enhanced by local-
izing the HRCT pattern scores to the biopsy site, the fol-
lowing analysis was performed: 24 cases had biopsies
taken from either the right or left upper lobe and 40 had
biopsies taken from the right lower or left lower lobe.
Total disease extent scores, all HRCT pattern scores and
traction bronchiectasis scores were recalculated for the
upper two levels (‘upper zone’ scores) and for the lower
two levels (‘lower zone’ scores). The analysis was re-
peated within these subgroups with the appropriate
‘upper zone’ or ‘lower zone’ HRCT variables. In both
analyses, the explanatory power of traction bronchiec-
tasis increased when compared to the analysis performed
using ‘whole lung’ HRCT variables and was also the
only independent predictor of FF score (upper zone:
r2 = 0.56, P < 0.0001, 95%CI 0.32–0.86, lower zone: r2 =
0.48, P < 0.0001, 95%CI 0.34–0.74).
Relationships between fibroblastic foci score and HRCT
patterns in fibrotic lung disease subgroups
The same analysis was performed in each diagnostic
subgroup. On univariate analysis, significant correlations
were identified between FF score and traction bronchiec-
tasis scores in patients with IPF/UIP, CTD related UIP,
and CHP (Table 3). Increasing extent of reticulation also
correlated with increasing FF score in patients with
CHP. On multivariate regression analysis the only sig-
nificant independent predictors of increasing FF score
were increasing severity of traction bronchiectasis in pa-
tients with IPF/UIP (n = 66, r2 = 0.19, P < 0.0001) and
patients with CHP (n = 49, r2 = 0.45, P < 0.0001). To de-
termine if patients with a histopathologic pattern of UIP
within the CHP group were disproportionately impact-
ing this observation, the CHP group was separated into
patients assigned a diagnosis of CHP on histopathologic
Table 1 Patient demographics, mean ± SD HRCT scores and
median (range) histopathologic scores in MDT diagnosis
subgroups
*Fibrotic NSIP *IPF/UIP CHP
(n=43) (n=70) (n=49)
Age 52.3±13.2 62.3±10.2 65.3±14.2
Gender (male/female) 19/24 58/11 25/24
Smoking (never/ever/current) 25/16/2 24/6/4 35/13/1
Total disease extent 31.5±22.5 36.3±20.4 37.6±28.3
Groundglass opacification 17.2±15.4 14.5±15.8 25.5±27.5
Reticulation 13.1±12.7 18.5±10.9 9.6±9.7
Honeycombing 0.45±1.9 2.2±5.9 1.2±5.4
Consolidation 0.1±0.1 0.1±0.1 0.2±0.1
Emphysema 0.49±1.76 1.2±4.1 0.9±4.3
Traction bronchiectasis 1.0±0.9 1.7±1.8 1.1±1.7
FF score 0.0 (0–1) 2.5(0–5.5) 1.5(0–5)
*NSIP =idiopathic non-specific interstitial pneumonia and connective tissue
disease related non-specific interstitial pneumonia combined, *IPF/UIP =idiopathic
pulmonary fibrosis and connective tissue disease related usual interstitial
pneumonia combined, CHP=chronic hypersensitivity pneumonitis
Table 2 Univariate correlations between FF scores and HRCT
variables expressed as Spearman’s rank correlation coefficient
(n=162)
FF score
r P value
Total disease extent 0.10 0.22
Groundglass opacification −0.09 0.21
Reticulation 0.42 <0.0001
Honeycombing 0.21 0.01
Consolidation 0.04 0.58
Traction bronchiectasis 0.50 <0.0001
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analysis (n = 29) and those with a histopathologic
pattern other than CHP (UIP-like = 16, NSIP-like = 4).
In this analysis severity of traction bronchiectasis
was the only HRCT pattern which independently
correlated with FF score in patients with concordant
histopathologic and MDT diagnoses of CHP (r2 = 0.64,
P < 0.0001).
Variables correlated with severity of traction
bronchiectasis patterns in disease subgroups
Variables which independently correlated with severity
of traction bronchiectasis were determined by the same
methods above, using severity of traction bronchiectasis
as the dependent variable. Three separate subgroups
were evaluated:IPF/UIP (n = 70), a combined group of
idiopathic fibrotic NSIP and connective tissue disease re-
lated NSIP (n = 43) and CHP (n = 49). In patients with
IPF and CHP, only FF score correlated with severity of
traction bronchiectasis. In the combined fibrotic NSIP
group, only increasing total disease extent and decreas-
ing extent of emphysema independently correlated with
severity of traction bronchiectasis (Table 4). When the
CPI was included in each of these analyses (representing
global physiologic disease severity), the same variables
were retained in each equation with the same statistical
significance.
Discussion
Our study has demonstrated, for the first time, that
fibroblastic foci profusion on histopathologic analysis
correlates most strongly with severity of traction bronchi-
ectasis shown on HRCT images. On analysis of subgroups
Table 4 Correlation of severity of traction bronchiectasis with HRCT pattern extents and fibroblastic foci scores on multivariate linear
regression within disease subgroups
HRCT pattern Partial regression coefficient P value 95 % CI
*IPF/UIP (n=70) r2 = 0.34 FF score 0.49 <0.0001 0.17–0.80
Global disease extent −0.02 0.74 −0.12–0.08
Extent of reticulation 0.04 0.03 0.00–0.08
Extent of ground glass 0.01 0.09 −0.02–0.03
Extent of honeycombing 0.02 0.61 −0.05–0.08
Extent of consolidation −0.26 0.63 −1.30–0.79
Extent of emphysema −0.31 0.05 −0.60– −0.01
*Fibrotic NSIP (n=43) r2 = 0.58 FF score 0.29 0.29 −0.27–0.86
Global disease extent 0.03 <0.0001 0.02–0.69
Extent of reticulation 0.03 0.27 −0.02–0.08
Extent of ground glass 0.004 0.60 −0.01–0.02
Extent of honeycombing 0.01 0.76 −0.07–0.09
Extent of consolidation 0.04 0.74 −0.66–0.91
Extent of emphysema −0.31 0.04 −0.60– −0.01
CHP (n=49) r2 = 0.35 FF score 0.72 <0.0001 0.43–1.00
Global disease extent −0.02 0.67 −0.13–0.08
Extent of reticulation 0.03 0.27 −0.02–0.08
Extent of ground glass 0.004 0.60 −0.01–0.02
Extent of honeycombing 0.01 0.76 −0.07–0.09
Extent of consolidation 0.04 0.74 −0.66–0.91
Extent of emphysema −0.73 0.05 −1.46– −0.01
*Fibrotic NSIP group = idiopathic fibrotic NSIP (n=25) and CTD-NSIP (n=18) combined. NSIP= non-specific interstitial pneumonia. *IPF/UIP =idiopathic pulmonary
fibrosis and connective tissue disease related usual interstitial pneumonia combined. CHP=chronic hypersensitivity pneumonitis
Table 3 Univariate correlations between FF scores and HRCT
variables expressed as Spearman’s rank correlation coefficient, in
patient MDT diagnosis subgroups
*Fibrotic NSIP IPF/UIP CHP
(n=43) (n=70) (n=49)
Total disease extent 0.04 (0.80) 0.12 (0.31) 0.02 (0.88)
Groundglass opacification −0.07 (0.64) 0.10 (0.42) −0.15 (0.31)
Reticulation 0.15 (0.34) 0.22 (0.07) 0.52 (0.001)
Honeycombing 0.18 (0.05) −0.06 (0.62) 0.372 (0.01)
Consolidation 0.02 (0.75) 0.09 (0.45) −0.02 (0.85)
Traction bronchiectasis 0.60 (0.77) 0.44 (<0.0001) 0.61 (<0.0001)
Numbers in parentheses are P values. *NSIP =idiopathic non-specific interstitial
pneumonia and connective tissue disease related non-specific interstitial
pneumonia combined, *IPF/UIP =idiopathic pulmonary fibrosis and connective
tissue disease related usual interstitial pneumonia combined, CHP=chronic
hypersensitivity pneumonitis
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stratified according to MDT diagnosis, severity of traction
bronchiectasis remained the only HRCT pattern that
correlated with fibroblastic foci profusion in patients with
an MDT diagnosis of IPF and CHP.
The histopathologic appearances of UIP are character-
ized by a temporally and spatially heterogeneous inter-
mix of normal lung, well-established acellular bundles of
collagen with microscopic honeycombing and areas of
new myxoid matrix containing aggregates of actively
proliferating and collagen-producing myofibroblasts,
the so-called ‘fibroblastic foci’. These foci are clinic-
ally important because in IPF their profusion on surgical
lung biopsy predicts physiologic decline and mortality
[7, 8, 26, 27]. Over the last 10 years, there has been a
growing reliance on clinical and chest-imaging criteria
to diagnose IPF, with surgical lung biopsy usually be-
ing reserved for cases in which the diagnosis remains
unclear on clinical and imaging grounds alone. This
shift in diagnostic thinking has primarily been driven
by changes in perception regarding histopathology as
a diagnostic gold standard, as well as the widely accepted
observation that in idiopathic fibrotic lung disease a
typical HRCT pattern of UIP is sufficient to secure a
diagnosis of IPF in the majority of cases [23, 28, 29].
Consequently, the clinical applicability of fibroblastic foci
profusion as a marker of prognosis is limited to a small
minority of patients. By contrast, HRCT imaging is rou-
tinely performed in patients with diffuse lung disease, and
several HRCT patterns, in particular honeycombing and,
more recently, traction bronchiectasis, have been reported
as prognostically important in several different fibrotic
lung diseases [2, 4–6, 21, 22]. Based upon these observa-
tions, we formed an a priori hypothesis that one or more
individual HRCT patterns may be a surrogate marker of
fibroblastic foci profusion.
The key observation in our study was that severity of
traction bronchiectasis correlates with fibroblastic foci
profusion on histopathologic analysis, which confirms
our original hypothesis. This finding was reinforced by
three separate observations. First, when a subgroup ana-
lysis of patients who had upper or lower lobe surgical
lung biopsies was performed using modified ‘upper zone’
and ‘lower zone’ traction bronchiectasis scores respect-
ively, the explanatory power of traction bronchiectasis
scores was improved when compared to traction bron-
chiectasis scores generated from all six levels of the
lungs. Second, on two multivariate analyses, adjusted for
disease severity, first using total disease extent on HRCT
and second using the CPI, traction bronchiectasis was
the only variable which independently correlated with
fibroblastic foci profusion. In this analysis, the relation-
ship between fibroblastic foci profusion and severity of
traction bronchiectasis was not influenced by the mode
of scoring global disease severity. Third, when predictors
of severity of traction bronchiectasis were investigated
using traction bronchiectasis as the dependent variable,
fibroblastic foci score was the variable which most
strongly correlated.
Once the FF-traction bronchiectasis relationship had
been established within the entire cohort, it was predict-
able that it remained robust in patients with an MDT
diagnosis of IPF. Both fibroblastic foci profusion and
traction bronchiectasis have been shown to be im-
portant predictors of mortality in patients with IPF,
and IPF patients within our cohort had the highest
mean traction bronchiectasis scores and highest me-
dian FF scores, thus empowering this subgroup for
analysis [2, 21, 22].
The relationship between severity of traction bronchi-
ectasis and fibroblastic foci profusion in patients with an
MDT diagnosis of CHP was less expected. It is well rec-
ognized that patients with an MDT diagnosis of CHP
may have pathologic appearances which are identical to
those of UIP [15, 30, 31]. Based upon the established re-
lationship between traction bronchiectasis and FF scores
in patients with IPF, we performed a subgroup analysis
within the CHP group, stratifying by pathologic appear-
ance, to determine if an underlying pattern of UIP was
disproportionately impacting our observations in this
CHP group. Although the FF-traction bronchiectasis
relationship remained robust in patients whose biopsies
had specifically been assigned an MDT diagnosis of
CHP, even in these cases, the distinction between UIP
and CHP might often be considered a matter of fine
judgment — one that is determined only by variable
degrees of inflammation, granuloma formation and
bronchocentricity (depending on how active the HP
component is). Relatively few studies have evaluated the
frequency of CHP on histopathologic analysis in the
setting of an MDT diagnosis of CHP, and those that have
are limited by small patient numbers [15, 31]. In a study
involving 25 cases of CHP diagnosed on clinico-
radiologic-pathologic grounds, Churg et al. reported that
18 (72 %) had a pathologic pattern of fibrosis predomin-
antly suggestive of UIP, with some added bronchocentric
fibrosis associated with fibroblastic foci [15]. The
remaining 7 cases had NSIP-like appearances (n = 4) or
showed only bronchocentric fibrosis (n = 3). Our results
in the CHP subgroup may reflect the degree of overlap
that exists between the pathologic appearances of UIP/
IPF and CHP. It is noteworthy that although there were
only 4 cases of connective tissue related UIP, at least on
univariate analysis, a significant correlation was demon-
strated between FF score and severity of traction bron-
chiectasis in these patients. It is possible that the
relationship between FF score and severity of traction
bronchiectasis we have observed is confined to patients
with UIP.
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Our findings in the fibrotic NSIP subgroup support
this conclusion. A key feature that distinguishes fibrotic
NSIP from UIP is the relative paucity of fibroblastic foci
seen in the former. The purpose of including patients
with a histopathologic diagnosis of fibrotic NSIP in our
analysis was to ensure that the full range of possible FF
scores (including a score of zero) was captured. In the
current study, of the 25 patients with an MDT diagnosis
of idiopathic NSIP, 20 cases were assigned an FF score of
zero by at least one pathologist (12 by both patholo-
gists). Of the 18 patients in the connective tissue disease
related fibrotic NSIP group, 15 cases were assigned an
FFscore of zero by at least one pathologist (10 by both
pathologists). Consequently, in both idiopathic and con-
nective tissue disease related fibrotic NSIP, no relation-
ship between severity of traction bronchiectasis and
fibroblastic foci profusion was identified on any of the
analyses. In a recent study of patients with connective
tissue disease related fibrotic lung disease, moderately
high traction bronchiectasis scores (using the same
method of scoring as the present study) were reported
in a subgroup (n = 26) of patients with biopsy proven
fibrotic NSIP [4]. In the current study, when combining
patients with idiopathic and connective tissue related
fibrotic NSIP, disease severity on HRCT, reflected by
total disease extent scores, correlated with the severity
of traction bronchiectasis rather than fibroblastic foci
profusion. Thesedata, as well as anecdotal evidence,
suggest that there are other factors, possibly global dis-
ease severity, which play a more significant role than
fibroblastic foci profusion alone in determining sever-
ity of traction bronchiectasis in patients with fibrotic
NSIP.
It is important to highlight that the results of this
study do not indicate a causal relationship between
fibroblastic foci profusion and severity of traction
bronchiectasis. This is supported, first by the observa-
tion that no significant correlation between FF score
and severity of traction bronchiectasis in patients with
fibrotic NSIP was demonstrated, and second by well-
established observations of severe traction bronchiec-
tasis in disease entities in which fibroblastic foci are
not generally considered a major component, such as
end stage fibrotic sarcoidosis, drug-induced fibrosis or
radiation-induced fibrosis. While the contractile forces
of fibroblastic foci may contribute to severity of trac-
tion bronchiectasis as our results suggest, the rela-
tionship is clearly not straightforward.
Our study has some limitations. It was retrospective in
design, and spanned 13 years, over which time there have
been changes in diagnostic guidelines regarding fibrotic
lung disease subsets, especially regarding the role of CT
in the diagnosis of IPF. However, all diagnoses were made
based on currently accepted histopathologic criteria and
following MDT collaboration, which is now regarded as
the diagnostic gold standard for diffuse lung diseases
[23]. Another possible limitation of the study is that all of
the patients underwent surgical lung biopsy, meaning
that imaging and clinical parameters were insufficient for
a secure diagnosis to be made. Consequently, our study
cohort may not replicate an unselected patient popu-
lation with fibrotic lung disease, in which only a
small proportion of patients usually proceed to biopsy
for diagnosis. We emphasize, however, that this was
an HRCT-histopathologic correlative study with a
specific aim: to identify links between fibroblastic foci
and HRCT patterns in fibrotic lung disease. Only 17
of the 162 patients had surgical lung biopsies taken
at more than one site and fibroblastic foci were
scored using a semiquantitative method. This limited
sampling and method of scoring could have impac-
tedFF score accuracy. It is worth highlighting that
quantification of fibroblastic foci, which most likely
represent a three-dimensional structure within the
lung on two-dimensional biopsy slides, may also im-
pact accuracy [32]. Regardless, all of the biopsy speci-
mens were evaluated by pathologists with expertise in
the histopathology of interstitial lung disease.
Conclusions
In conclusion, we have demonstrated that the severity of
traction bronchiectasis shown on HRCT independently
predicts fibroblastic foci profusion in patients with IPF
and CHP. This finding possibly explains the growing
evidence that severity of traction bronchiectasis is an im-
portant predictor of prognosis in several different fibrotic
lung diseases.
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